Embodiments relate generally to ultrasound therapy systems and methods and more particularly to a non-contact, low-frequency, highly efficient ultrasound therapy system that delivers ultrasonic therapy treatments via a mist to a patient wound to promote wound healing.
Use of ultrasonic waves to promote healing of wounds has become more common in recent years as its benefits are better understood and this type of therapy becomes more widely utilized. In general, ultrasonic waves have been used in medical applications for a long time, including diagnostics, therapy, and industrial applications.
A number of innovative ultrasound therapy systems and devices have previously been developed including non-contact, ultrasound mist therapy devices by the assignee of the current application, Celleration, Inc. These systems and devices have been widely used for medical treatments in medical facilities around the world. See, for example, co-owned U.S. Pat. No. 6,569,099, entitled ULTRASONIC METHOD AND DEVICE FOR WOUND TREATMENT. Unlike most conventional wound therapies that are limited to treatment of the wound surface, Celleration, Inc., developed therapies in which ultrasound energy and atomized normal saline solutions were used to stimulate the cells within and below the wound bed to aid in the healing process.
Although these ultrasound therapies have been effective, devices, systems and methods providing improved ultrasonic therapies that are more accessible, safer to administer to patients, and more efficient in delivery of ultrasound energy have been widely desired.
Embodiments relate to non-contact, low-frequency, highly efficient ultrasound therapy devices, systems and methods that deliver ultrasonic therapy treatments via a mist to a patient wound to promote wound healing. One embodiment is directed to a non-contact, medical ultrasound therapy system for generating and controlling low frequency ultrasound. The ultrasound therapy system includes a treatment wand including an ultrasonic transducer, a generator unit, and a cable coupling the treatment wand to the generator unit. The generator unit generates electric power output to drive the ultrasonic transducer and includes a digital frequency generator, wherein the generator unit digitally controls energy output at resonance frequency of the ultrasonic transducer.
Another embodiment is directed to a highly efficient ultrasonic generator unit. The ultrasonic generator unit includes an ultrasonic driver with digital controls to maintain system displacement at resonance frequency of a transducer coupled to the ultrasonic generator unit. The ultrasonic driver in this embodiments includes a microprocessor, a digital frequency generator, and a phase detector.
A further embodiment is directed to an ultrasonic system. The ultrasonic system includes a user interface controlled by a first microprocessor, a treatment device including an ultrasonic transducer, and a generator unit including an ultrasonic driver controlled by a second microprocessor. In this embodiment both the first microprocessor and the second microprocessor are configured to individually suspend operation of the ultrasonic system in fault condition situations.
A further embodiment is directed to a method for digitally generating and controlling low frequency ultrasound used in a non-contact medical ultrasound therapy system. The method includes performing a power on self-test to an ultrasonic therapy system that includes a treatment wand containing an ultrasonic transducer and a generator unit containing an ultrasonic driver. The method further includes performing a frequency sweep using a sine wave to determine a resonance frequency of the ultrasonic transducer by evaluating and looking for a relative minimum impedance of the ultrasonic transducer. The method further includes adjusting the digital frequency generator output frequency based on voltage and current phase angle so that a frequency lockup is maintained at the resonance frequency, and monitoring voltage and phase detection circuits of the ultrasonic therapy system for phase difference.
The invention may be more completely understood in consideration of the following detailed description of various embodiments of the invention in connection with the accompanying drawings, in which:
Various embodiments may be embodied in other specific forms without departing from the essential attributes thereof, therefore, the illustrated embodiments should be considered in all respects as illustrative and not restrictive.
A need for a more accessible and safer ultrasonic therapy device and system for patients to use has been recognized in this disclosure. Further, many of the substantial technical obstacles to providing such a device based on the requirements of conventional ultrasound therapy devices are recognized and overcome by this disclosure. Specifically, making devices more readily accessible to additional patient populations has been a significant problem due to the very high voltage necessary to operate conventional devices. For example, some conventional ultrasound therapy devices have operated at about 700 Volts (V) and 7 Watts (W) of energy. This has necessitated qualified oversight of therapy provision, as allowing patients to operate such a high voltage machine on their own might otherwise present a significant safety risk. Further, the energy requirements have made the possibility of a portable battery powered device, which could be used in a homecare environment, unfeasible. Ultrasound therapy systems described herein, however, overcome many or all of the technological obstacles of the past and provide a lower-power, safer, more efficient, and more accessible ultrasound therapy system. Even battery powered systems are possible in certain embodiments. Accordingly, designs for new medical ultrasound devices, systems and methods incorporating various features, concepts and improvements, are described in the following detailed description.
Generator unit 30 and treatment wand 40 are connected by a cable 90. Ultrasonic driver 60 comprises hardware mounted inside generator unit 30. A basic function of the ultrasonic driver 60 is to generate electric power output to drive ultrasonic transducer 70. Ultrasonic transducer 70 includes an acoustic horn 100 and related assembly mounted inside treatment wand 40. Ultrasonic transducer 70 converts and transfers input electrical power into vibrational mechanical (ultrasonic) energy that will be delivered to the treatment area (i.e. to a patient wound area via atomized saline). Treatment wand 40 contains the system's user interface 110 and controls for parameters of the treatment, though in other embodiments an additional or alternative user interface can be incorporated in generator unit 30. Treatment wand 40 is configured to appropriately position and hold applicator 80 relative to acoustic horn 100 for proper delivery of fluid during operation. The configuration also provides appropriate atomization of saline fluid and delivery of the resulting mist and ultrasound energy to a wound treatment area.
Fluid management pump 50 provides a fixed flow rate of saline or other fluid (e.g., about 0.9% normal saline in one embodiment) via a tube 120 to the distal tip 140 of ultrasonic transducer 70 from a saline bag 130 or other source, as appropriate. The saline fluid is delivered to the radial surface of transducer horn near its tip 140. The saline fluid is dispensed through an orifice on a superior surface of the horn 100, and a portion of the saline is displaced forward to the face of horn 100 and atomized by horn 100 when it is energized and operating. The remaining volume of fluid is fed to an inferior surface of ultrasonic transducer 70 via gravity and capillary action. When a sufficient volume of saline is accumulated, transducer tip 140 atomizes the saline into a plume. The atomized saline spray plume emanates from two points on the ultrasonic transducer 70, i.e., generally at the 12 o'clock and 6 o'clock positions given normal positioning of treatment wand 40 in operation, forming intersecting spray paths at approximately 5 mm from the front face of ultrasonic transducer 70 in some embodiments. In other embodiments, treatment wand 40, transducer 70, horn 100, tip 140 and/or other components can be designed to provide a differently sized or configured spray plume and paths.
Treatment wand 40 houses ultrasonic transducer 70 and includes a microprocessor 200, various interface and sensing components, and an OLED display 206. Treatment wand 40 is pistol-shaped in embodiments to provide an improved ergonomic operator design, though other configurations can be implemented as may be advantageous in some applications. Treatment wand 40 comprises an acoustic horn assembly (e.g., piezo elements, back mass, horn and booster), ultrasonic transducer 70, microprocessor (MCU2) 200, user control key pad 202 and trigger 204, and an LCD screen display 206 that displays operational information and enables control and programming of the treatment therapy (see, e.g.,
User interface 110 on treatment wand 40 includes key pad 202, trigger 204, and screen display 206. In some embodiments, display 206 can be a full-color OLED display, and key pad 202 can be a four button display, as shown in
Microprocessor 200 that controls user input requirements can also measure the internal temperature of treatment wand 40, or of transducer 70 or horn 100 more specifically, from ultrasonic transducer sensor 210 and treatment wand sensor 212. Microprocessor 200 also sends read/write information to applicator 80. Microprocessor 200 communicates with generator unit 30 via an RS488 transceiver 214 and writes information to EEPROM 216. This information is stored and can be retrieved for understanding the use and performance of the system. Accordingly, greater detail can be given on data stored, how much, how long and how retrieved (USB upload/download by the user, service or other).
RFID transceiver 208 of treatment wand 40 can be used to communicate with an RFID tag (not shown) for applicator detection, as previously mentioned. The RFID tag can be located on applicator 80, and microprocessor 200 in treatment wand 40 can serve as an RFID reader and writer of the signals received via RFID transceiver 208. Specifically, an RFID controller can be used in treatment wand 40 for a Read/Write RF tag on applicator 80. In each new treatment, system 10 will require a new applicator 80. The RFID controller can read the ID tag of applicator 80 to identify if that particular applicator 80 is new or used. After a particular applicator 80 is used for a specified period of time, the RFID controller can write the information to an ID tag to identify that applicator 80 has been used to avoid reuse.
Microprocessor 200 of treatment wand 40 can be used to control all inputs and output functions and perform all control loops, and calculations. Features of some embodiments can include: an 80 MHz maximum frequency; 1.56 DMIPS/MHz (Dhrystone 2.1) performance; an operating voltage range of 2.3V to 3.6V; a 512K flash memory (plus an additional 12 KB of Boot Flash); a 128K SRAM memory; a USB 2.0-compliant full-speed device and On-The-Go (OTG) controller; up to 16-channel, 10-bit Analog-to-Digital Converter; six UART modules with RS-232, RS-485 and LIN support; and up to four SPI modules. These features are merely examples of one embodiment and can vary in other embodiments.
Ultrasonic transducer 70 generally comprises a piezoelectric ceramic element and metal horn 100 mounted in a sealed housing. The ultrasonic transducer input can be an AC voltage or AC current, and the waveform can be a square form or sine form. The ultrasonic transducer output is mechanical vibration of the tip of transducer 70. The amount of energy output depends on tip 70 displacement, operation frequency, size and driver load (e.g., air or liquid mist). The ratio of output to input energy is referred to as the electromechanical coupling factor. There are many variables that affect coupling factor, including operation frequency. In theory, it would be advantageous to operate a US Transducer (UST) by keeping the operating frequency in the resonance frequency (Fr) or anti-resonance frequency (Fa) region because its electrical power factor is 1. However, due to the related, very unique impedance-frequency characteristics of these transducers, which can vary from transducer to transducer, drive circuit design is very difficult. In previously designed ultrasonic drivers, Phase Loop Lock (PLL) techniques were widely used. Because of the nature of analog performance, keeping a highly accurate and stable frequency output was very difficult. In theory, an ultrasonic transducer that operates at Fr or Fa has a high efficiency output. In practice, operating a UST at Fr or Fa is almost impossible with PLL technology. This is why most ultrasonic drivers with a PLL design only can operate in Fr or Fa regions rather than at Fr or Fa points, and the operational phase typically must be more than 50 degrees. For most systems with rapidly changing load impedance, operation at frequencies close to Fa or Fr will cause the system to be unstable. Alternatively, a system can be kept running stable by setting the operation frequency lower than Fr or higher than Fa points, as in past designs. In embodiments discussed herein, however, the ultrasonic driver can be monitored and controlled to operate at or very near Fr, a significant advantage over conventional systems.
Ultrasonic transducer 70 is operated at relatively large displacements and a low load condition, thereby reducing loading effects and electrical impedance. Accordingly, ultrasonic medical applications use a constant current control algorithm because of the following performance advantages: increased electrical safety due to lower operating voltage; proportional current to tip velocity (displacement if frequency is held constant); and the capability to limit excessive power surges by setting the voltage rail to an appropriate value, among others.
Generator unit 30 includes a power entry module and AC/DC power supply 300 as well as an ultrasonic driver 60. Delivery pump 50 is mounted on generator unit 30 and is controlled by a pump driver located on ultrasonic driver 60. Communications ports 302, 304, and 306 are also located on the generator unit 30, though the number and arrangement of communications ports can vary from those depicted. For example, in other embodiments more or fewer ports are provided, and one or more of the ports can comprise a wireless communications port (e.g., infrared, RF, BLUETOOTH, WIFI or some other wireless technology). These ports provide an information exchange between generator unit 30 and treatment wand 40 as well as information exchange between device 20 and user.
With respect to the Power Entry Module & AC/DC Power Input, in some embodiments the local AC MAINS is connected to an appliance inlet with a hospital grade detachable power cord. In some embodiments, two power cords will be used, 15 A with a 125V rate and 10 A with a 250V rate. In some embodiments, the appliance inlet is a power entry module listed for medical applications with an 10 A current rating, 120/250 VAC voltage input, MAINS switch, integral fuse holder (2¼×1¼″/5×20 mm fuses), EMC line filter for medical applications, and is mounted on the rear panel of the chassis. Although not depicted in the figures, embodiments are contemplated that use battery power as the power source in the system's design. The battery would be located within generator 30 in various embodiments. Battery power is made possible due to the extremely efficient design discussed herein.
In some embodiments, system 10 can have a universal AC power input capability accepting a range of power input from 90V to 265 VAC. The local AC MAINS are connected to an appliance inlet component (IEC 320 C14) with a hospital grade detachable power cord. The appliance inlet is a power entry module listed for medical applications with an 115V/230V voltage input, MAINS switch, integral fuse holder (2-5×20 mm fuses), and an EMC line filter for medical applications that is mounted on the rear panel of the chassis. The MAINS switch output is connected to two AC/DC switching power modules. The two AC/DC (24V output) switching power supply modules are serially connected together to provide +/−24V power to AB type amplifier use. All DC power sources +5V, +4.5V, −4.5V and 3.3V are generated from +24 VDC—power source via DC/DC converter. The +5 VDC will provide 5V power to treatment wand 40 through the detached cable and medical grade connector 90.
In some embodiments, two identical AC/DC (24V output) switching power supply modules are serially connected together to provide +/−24V power to AB type amplifier use. The power supply can be medical grade, Class II, BF rated with 45 W output with conventional cooling. A dual color (Red/Green) LED 308 can be mounted at the front of generator unit 30. The green color indicates normal power on without errors, and the red color indicates a system error or failure. Error detail information can also display on the interface display screen 206 of treatment wand 40.
In some embodiments, there are a plurality of, such as three, communication ports in the on generator 30. The first port is a RS488 communication port 302, with 5V power and XD outputs. This port 302 is connected to treatment wand 40 through cable 90. Port 302 can be configured for full duplex communications in both directions at the same time. This port 302 can handle information exchange between generator unit 30 and treatment wand 40. In operation, both sets of microcontrollers 200 and 316 can check each other to ensure none has failed to operate through this port 302. The second port can be a USB-2 type A port, referred to herein as port 304. It can be designed for user download of information stored at the EEPROM memory 310 by using flash key device. This port 304 can be used for uploading software from flash key device. A third port can be an RS232-3.3V serial port, referred to herein as port 306. Port 306 can be designed for use with a PC, so the PC can communicate to the system 10 for download, upload, system debug and calibration. Also included in generator unit 30 and connected to the microcontroller are RTC DS1306 at numeral 305, audible signal generator 307 and generator temperature sensor 309.
A microcontroller controlled pump delivery system 312 can be used for fluid delivery. Delivery system 312 comprises a pump 50 and pump driver with controls 314 for pump speed and pump door monitoring and can deliver fluid, such as saline, through a tube 120 and applicator 80 to the tip of ultrasonic transducer 70. Microcontroller (MCU1) 316 of generator unit 30 can control peristaltic pump speed to control saline flow rate for a fixed tubing size. Pump delivery system 312 generally operates at constant flow rate for all operating conditions. A cooling fan 317 is mounted in the back of generator unit 30. It is controlled by microcontroller 316 of ultrasonic driver 60.
Ultrasonic driver 60 includes a microprocessor 316 that controls, measures and monitors the drive electronics and communicates with the hardware and software of the treatment wand 40. In some embodiments, ultrasonic driver 60 includes a microprocessor 316 (such as Microchip Technology Inc. PIC32) with an 80 MHz clock and 1.56 DMIPS/MHz performance, though some other suitable microprocessor can be used in other embodiments. The drive electronics contain a digital frequency generator (DDS) 318, AC amplifier 320 and voltage and current phase detection circuits 322 and 324. Digital frequency generator 318 generates accurate frequencies set by microprocessor 316 to AC amplifier 320 that are output via impedance match 326 to ultrasonic transducer 70. Voltage and current phase detection circuits 322 and 324 continually monitor the phase difference sensed at 328. In operation, microprocessor 316 can adjust the digital frequency generator output frequency based on voltage and current phase angle so that the frequency is locked at the resonance frequency Fr of ultrasonic transducer 70. The resonance frequency Fr is not a fixed frequency, however, as it can drift with temperature and other changes. This is discussed herein below in additional detail.
Ultrasonic driver 60 includes a digital frequency generator 318, a resonance frequency control loop 400, and an output current control loop 500. Microcontroller 316 can be of sufficiently high speed so as to handle all input measures and output settings, especially for phase comparison of cycle by cycle frequency adjustment in real time. Ultrasonic driver 60 generates electrical output with an ultrasonic frequency and a required power.
At Fr and Fa, the impedance phase is 0 degrees, which means that ultrasonic transducer 70 can achieve the highest power efficiency at those points. Accordingly, it is recognized that keeping the output frequency close to Fr or Fa would be desirable, if possible. However, it is very difficult for any control systems to operate at Fr and Fa, as at those points any small increase or decrease of frequency will cause a large impedance increase or decrease. Accordingly, most ultrasonic drivers either operate at frequencies higher than Fa or lower than Fr because frequencies are relatively stable when they are farther from Fr or Fa.
For example, some conventional systems have been designed to operate in the Fa region. These designs were relatively stable and delivered effective treatment, but output power efficiency was very low and a very high operating voltage was required. Accordingly, in order to meet regulatory safety requirements, wires with high isolation and earth protection were required, adding cost and restricted user ergonomics due to a stiffer and heavier cable.
An example comparing the voltage required by a past device operating at Fa compared to an embodiment of the currently disclosed system, operating at Fr, is set forth below:
A conventional ultrasonic transducer was operated at anti-ultrasonic region which is approximately 1KΩ˜8KΩ impedance. To deliver the required power to the transducer the driver must output very high voltage (300V) to the transducer. The power calculation is:
P=I2Z*Cos φ Equation 1
If the transducer requires 7 W power, φ=85°, Z=1500Ω, from Equation 1 the current will be:
Accordingly, a power supply voltage would be: (230 mA*1500Ω)=347V.
An embodiment of system 10, in contrast, operates at Fr with constant current output control. Its impedance is about 25˜80Ω and voltage current phase angle close to 0 degrees. The power efficiency is almost 100%. An example with Fr impedance is 50Ω.
If the transducer requires 7 W power, Ω=0°, Z=50Ω, the current will be:
and the power voltage will be: 370 mA*50Ω=18.7V
Accordingly, embodiments of system 10, with a low voltage operation condition, can be much more efficient and safer than conventional designs. Any voltage surges resulting when transducer impedance is increased can be limited by setting the voltage rail to an appropriate value.
Microcontroller 316 of the ultrasonic driver controls all input and output functions and performs all control loops, calculations. Certain embodiments of microcontroller 316 may include one or more of the following: a 80 MHz maximum frequency; 1.56 DMIPS/MHz (Dhrystone 2.1) performance; an operating voltage range of 2.3V to 3.6V; a 512K flash memory (plus an additional 12 KB of Boot Flash); a 128K SRAM memory; USB 2.0-compliant full-speed device and On-The-Go (OTG) controller; up to 16-channel, 10-bit Analog-to-Digital Converter; six UART modules with RS-232, RS-485 and LIN support; and up to four SPI modules. These characteristics are merely examples and can vary in other embodiments.
The ultrasonic frequency generator is a digital frequency generator 318 that provides numerous advantages over conventional designs. In some conventional designs, PLL technology was used with a voltage control oscillator (VCO) for generating a fixed ultrasonic frequency. However, this produced an output frequency that is low resolution and not flexible for wide frequency range applications without hardware changes. Further, the frequency stability was imprecise since the VCO is affected by temperature, noise and power ripple.
In the current ultrasonic therapy system 10, a Direct Digital Synthesis programmable frequency generator (DDS) is used as part of the frequency generator 318. Because a DDS is digitally programmable, the phase and frequency of waveform can be easily adjusted without the need to change the external components that would normally need to be changed when using traditional analog-programmed waveform generators. DDS permits simple adjustments of frequency in real time to locate resonance frequencies or compensate for temperature drift. The output frequency can be monitored and continually adjusted by microcontroller 316 at real time speed. Advantages of using DDS to generate frequency include: digitally controlled micro-hertz frequency-tuning and sub-degree phase-tuning capability; extremely fast speed in tuning output frequency (or phase); and phase-continuous frequency hops with no overshoot/undershoot or analog-related loop setting-time anomalies, among others.
The digital architecture of DDS eliminates the need for the manual tuning and tweaking related to components aging and temperature drift in analog synthesizer solutions, and the digital control interface of the DDS architecture facilitates an environment where systems can be remotely controlled and optimized with high resolution under processor control.
Specifically, when initially energized, microprocessor 316 can be programmed to perform a frequency sweep using a sine wave to determine the resonant frequency by evaluating and looking for a relative minimum impedance of ultrasonic transducer 70. The sweep is confined to a smaller defined interval based on the information embedded in treatment wand 40 regarding the operating characteristics of ultrasonic transducer 70. This includes the information stored in ultrasonic transducer 70 at the time of manufacture or otherwise programmed or updated. During the system start, digital frequency generator 318 can scan frequencies from a start frequency (min 20 KHz, adjustable) to an end frequency (max 50 KHz, adjustable) to find the resonance frequency (Fr). Microprocessor 316 can adjust the digital frequency generator output frequency based on voltage and current phase angle so that the frequency lockup is maintained at the resonance frequency of ultrasonic transducer 70 (i.e., at a 0° phase angle). Because the frequencies continually shift due to temperature change and other factors, the phase of output voltage and current will change as well. The voltage and current phase detection circuits are continually monitored for the phase difference and adjusted accordingly. Resonance frequency is not a fixed frequency. This is due to heating and other factors causing a slight drift change with temperature. Specifically, increased temperature can cause decreased resonant frequency.
In order to keep output frequency lockup at resonance frequency, frequency control loop 400 can operate at the real time monitoring output voltage and current phase angle and continually adjust operating frequency to match the current resonance frequency. In some embodiments, microprocessor 316 can maintain Δφ (as illustrated at 390) to less than about 0.1 degree inaccuracy and provide sufficient capabilities to achieve accuracy of about 0.1 Hz or better. In some embodiments, resonance frequency is digitally controlled to better than about 0.5 Hz while maintaining constant energy output.
In system 10, the digital frequency generator 318 can be used to allow for selection and use of different frequencies via software implementation. Configurations having frequencies ranging from about 20-50 kHz are possible. Digital frequency generator 318 is digitally programmable. Accordingly, the phase and frequency of a waveform can be easily adjusted without the need to change hardware (frequency generating components), as would normally be required to change when using traditional analog-programmed waveform generators. Digital frequency generator 318 permits simple adjustments of frequency in real time to locate resonance frequencies or compensate for temperature drift or other deviations in the resonant frequency. The output frequency can be monitored and continually adjusted by microcontroller 316 at real time speed.
There are many advantages to using digital frequency generator 318 to generate frequency. For example, this provides a digitally controlled, 0.1-Hertz frequency-tuning and sub-degree phase-tuning capability as well as extremely fast speed in tuning output frequency (or phase). The digital frequency generator 318 also provides phase-continuous frequency loops with no overshoot/undershoot or analog-related loop setting-time anomalies. The digital architecture of the digital frequency generator 318 eliminates the need for the manual tuning and tweaking related to components aging and temperature drift in analog synthesizer solutions, and the digital control interface of the digital frequency generator architecture facilitates an environment where systems can be remotely controlled and optimized with high resolution under processor control.
In this system, ultrasonic driver 60 outputs a sine waveform through a class AB power amplifier 320. It can operate at frequency from 20 KHz to 50 KHz, constant current mode. The ultrasonic driver 60 outputs current from 0 to 0.5 A, voltage from 0 to 30 Vrms, Max power to 15 W. The ultrasonic driver output can scan resonance frequencies from the 20 KHz to 50 KHz range, detect minimum impedance (0° degree phase angle of voltage and current), and then lock operational frequency to resonance frequency of the ultrasonic transducer 70 at a ±0.5 Hz accuracy level. Parameters may vary in various embodiments. In certain embodiments, the drive voltage requirements are less than 50 Vrms for the system.
The technology of system 10 is unique in that sees an essentially constant load. The no-load condition is similar to the operational load. Being a non-contact treatment and dispensing only a small amount of fluid onto the horn does not create a significant variation in the load/output allowing the system to be run at resonance (Fr). Running and controlling the system at Fr allows greater efficiency, as previously discussed. Typical ultrasound applications such as welding, mixing, cutting, and cleaning have significant variation in the load, e.g., going from a no-load to full load condition. The variation makes control of the output very difficult and requires greater power at the cost of efficiency.
In system 10, a constant current control algorithm can be used. It can operates at resonance frequency, rather than just close to resonant frequency. The difference between anti-resonance and resonance is anti-resonance with highest impedance and resonance with lowest impedance. The high impedance can be range at 5KΩ˜50KΩ and lowest impedance can be at 20Ω˜100Ω in certain embodiments, for example.
Since ultrasonic transducer 70 is operated with relatively large displacements and a low load condition, there is a significant reduction in loading effects and electrical impedance variation. Many ultrasonic medical applications use a constant current control algorithm because of the following performance advantages: electrical safety (due to a lower operating voltage); current that is proportional to tip velocity (displacement if frequency is held constant); and fewer excessive power surges (by setting and maintaining the voltage rail to an appropriate value).
Some embodiments of system 10 have three modes of operation: a TREATMENT mode; an INFORMATION mode; and a TERMINAL mode. If the user enters the TREATMENT or normal operating mode upon power up, the user can select the length of time for a treatment and energize the acoustic output to treat a patient. If the INFORMATION mode is entered on power up with a flash key plug to the USB port, user information can be downloaded that has been stored in the memory to flash or new software can be uploaded from the flash key to the system. Finally, a TERMINAL mode can be selected that is an engineering mode for internal device calibration, system characterization, and system evaluation.
System 10 may also save all information of the device hardware and software as well as the user's input and treatments during operation. In some embodiments, system 10 has enough memory storage for all information saved for at least one year of operation. For example, system 10 may implement 2 MB bits EEPROM and flexible size memory in some embodiments.
If 714 is reached (in
If 720 is reached (in
When 754 is reached (
When 766 is reached (
As understood by the various system checks and protocols in this operational explanation, the operation of the system can be suspended at many points. Advantageously, in certain embodiments, both microprocessor 200 and microprocessor 316 are configured to individually suspend operation of the ultrasonic system in fault condition situations. This arrangement provides enhanced safety not present in other types of designs.
It should also be appreciated that the exemplary embodiment or exemplary embodiments are only examples, and are not intended to limit the scope, applicability, or configuration of the invention in any way. Rather, the foregoing detailed description will provide those skilled in the art with an enabling disclosure for implementing the exemplary embodiment or exemplary embodiments. It should be understood that various changes can be made in the function and arrangement of elements without departing from the scope of the invention as set forth in the appended claims and the legal equivalents thereof.
The embodiments above are intended to be illustrative and not limiting. Additional embodiments are within the claims. Although the present invention has been described with reference to particular embodiments, workers skilled in the art will recognize that changes may be made in form and detail without departing from the spirit and scope of the invention.
Various modifications to the invention may be apparent to one of skill in the art upon reading this disclosure. For example, persons of ordinary skill in the relevant art will recognize that the various features described for the different embodiments of the invention can be suitably combined, un-combined, and re-combined with other features, alone, or in different combinations, within the spirit of the invention. Likewise, the various features described above should all be regarded as example embodiments, rather than limitations to the scope or spirit of the invention. Therefore, the above is not contemplated to limit the scope of the present invention.
For purposes of interpreting the claims for the present invention, it is expressly intended that the provisions of Section 112, sixth paragraph of 35 U.S.C. are not to be invoked unless the specific terms “means for” or “step for” are recited in a claim.
Number | Name | Date | Kind |
---|---|---|---|
2534046 | Mau | Dec 1950 | A |
3433226 | Boyd | Mar 1959 | A |
2889852 | Dunlap | Jun 1959 | A |
3207181 | Willis | Oct 1963 | A |
3243122 | Snaper | Mar 1966 | A |
3275059 | McCullough | Sep 1966 | A |
3392916 | Engstrom | Jul 1968 | A |
3504887 | Okerblom | Apr 1970 | A |
3522801 | Robinson | Aug 1970 | A |
3561444 | Boucher | Feb 1971 | A |
3636947 | Balamuth | Jan 1972 | A |
3685634 | Bergling | Aug 1972 | A |
3685691 | Ianelli | Aug 1972 | A |
3685694 | Ianelli | Aug 1972 | A |
3765606 | Moss | Oct 1973 | A |
3860173 | Sata | Jan 1975 | A |
3874372 | LeBon | Apr 1975 | A |
3952918 | Poitras | Apr 1976 | A |
4052004 | Martin | Oct 1977 | A |
4085893 | Durley | Apr 1978 | A |
4153201 | Berger | May 1979 | A |
4185502 | Frank | Jan 1980 | A |
4192294 | Vasilevsky | Mar 1980 | A |
4251031 | Martin | Feb 1981 | A |
4271705 | Crostack | Jun 1981 | A |
4294407 | Reichl | Oct 1981 | A |
4301093 | Eck | Nov 1981 | A |
4301968 | Berger | Nov 1981 | A |
4309989 | Fahim | Jan 1982 | A |
4319155 | Nakai | Mar 1982 | A |
4331137 | Sarui | May 1982 | A |
4334531 | Reichl | Jun 1982 | A |
4352459 | Berger | Oct 1982 | A |
4414202 | Anthony | Nov 1983 | A |
4428531 | Martin | Jan 1984 | A |
4466571 | Muhlbauer | Aug 1984 | A |
4530360 | Duarte | Jul 1985 | A |
4541564 | Berger | Sep 1985 | A |
4551139 | Plaas et al. | Nov 1985 | A |
4582149 | Slaughter, Jr. | Apr 1986 | A |
4582654 | Karnicky | Apr 1986 | A |
4619400 | Van Der Burgt | Oct 1986 | A |
4642581 | Erickson | Feb 1987 | A |
4655393 | Berger | Apr 1987 | A |
4659014 | Soth | Apr 1987 | A |
4679551 | Anthony | Jul 1987 | A |
4726523 | Kokubo | Feb 1988 | A |
4726525 | Yonekawa | Feb 1988 | A |
4733820 | Endo | Mar 1988 | A |
4756478 | Endo | Jul 1988 | A |
4767402 | Kost et al. | Aug 1988 | A |
4783003 | Hirabayashi | Nov 1988 | A |
4790479 | Matsumoto | Dec 1988 | A |
4793339 | Matsumoto | Dec 1988 | A |
4815661 | Anthony | Mar 1989 | A |
4818697 | Liboff | Apr 1989 | A |
4849872 | Gassler | Jul 1989 | A |
4850534 | Takahashi et al. | Jul 1989 | A |
4877989 | Drews | Oct 1989 | A |
4883045 | Theisz | Nov 1989 | A |
4905671 | Senge | Mar 1990 | A |
4930700 | McKown | Jun 1990 | A |
4941614 | Ilott | Jul 1990 | A |
4941618 | Hildebrand | Jul 1990 | A |
4961885 | Avrahami | Oct 1990 | A |
4982730 | Lewis, Jr. | Jan 1991 | A |
5002059 | Crowley | Mar 1991 | A |
5013241 | Gutfeld | May 1991 | A |
5040537 | Katakura | Aug 1991 | A |
5045066 | Scheuble | Sep 1991 | A |
5062795 | Woog | Nov 1991 | A |
5063922 | Hakkinen | Nov 1991 | A |
5067655 | Farago | Nov 1991 | A |
5076266 | Babaev | Dec 1991 | A |
5104042 | McKown | Apr 1992 | A |
5115805 | Bommannan | May 1992 | A |
5134993 | van der L | Aug 1992 | A |
5143588 | Liboff | Sep 1992 | A |
5152289 | Viebach | Oct 1992 | A |
5163433 | Kagawa | Nov 1992 | A |
5171215 | Flanagan | Dec 1992 | A |
5172692 | Kulowet | Dec 1992 | A |
5186162 | Talish | Feb 1993 | A |
5197946 | Tachibana | Mar 1993 | A |
5211160 | Talish | May 1993 | A |
5219401 | Cathignol | Jun 1993 | A |
5231975 | Bommannan | Aug 1993 | A |
5259384 | Kaufman | Nov 1993 | A |
5269291 | Carter | Dec 1993 | A |
5309898 | Kaufman | May 1994 | A |
5314441 | Cusack | May 1994 | A |
5315998 | Tachibana | May 1994 | A |
5316000 | Chapelon | May 1994 | A |
5318014 | Carter | Jun 1994 | A |
5323769 | Bommannan | Jun 1994 | A |
5324255 | Passafaro | Jun 1994 | A |
5345940 | Seward | Sep 1994 | A |
5347998 | Hodson | Sep 1994 | A |
5362309 | Carter | Nov 1994 | A |
5374266 | Kataoka | Dec 1994 | A |
5376855 | Suganuma | Dec 1994 | A |
5380411 | Schlief | Jan 1995 | A |
5386940 | Berfield | Feb 1995 | A |
5393296 | Rattner | Feb 1995 | A |
5431663 | Carter | Jul 1995 | A |
5437606 | Tsukamoto | Aug 1995 | A |
5456258 | Kondo | Oct 1995 | A |
5515841 | Robertson | May 1996 | A |
5515842 | Ramseyer | May 1996 | A |
5516043 | Manna | May 1996 | A |
5520166 | Ritson | May 1996 | A |
5520612 | Winder | May 1996 | A |
5523058 | Umermura | Jun 1996 | A |
5527350 | Grove | Jun 1996 | A |
5529572 | Spector | Jun 1996 | A |
5545124 | Krause | Aug 1996 | A |
5547459 | Kaufman | Aug 1996 | A |
5551416 | Stimpson | Sep 1996 | A |
5554172 | Horner | Sep 1996 | A |
5556372 | Talish | Sep 1996 | A |
5573497 | Chapelon | Nov 1996 | A |
5611993 | Babaev | Mar 1997 | A |
5616140 | Prescott | Apr 1997 | A |
5618275 | Bock | Apr 1997 | A |
5626554 | Ryaby | May 1997 | A |
5630828 | Mawhirt | May 1997 | A |
5643179 | Fujimoto | Jul 1997 | A |
5656016 | Ogden | Aug 1997 | A |
5658323 | Miller | Aug 1997 | A |
5664570 | Bishop | Sep 1997 | A |
5688224 | Forkey | Nov 1997 | A |
5699805 | Seward | Dec 1997 | A |
5702360 | Dieras | Dec 1997 | A |
5707402 | Heim | Jan 1998 | A |
5707403 | Grove | Jan 1998 | A |
5725494 | Brisken | Mar 1998 | A |
5730705 | Talish | Mar 1998 | A |
5735811 | Brisken | Apr 1998 | A |
5743863 | Chapelon | Apr 1998 | A |
5752924 | Kaufman | May 1998 | A |
5762616 | Talish | Jun 1998 | A |
5785972 | Tyler | Jul 1998 | A |
5807285 | Vaitekunas | Sep 1998 | A |
5835678 | Li | Nov 1998 | A |
5843139 | Goedeke | Dec 1998 | A |
5875976 | Nelson | Mar 1999 | A |
5879314 | Peterson | Mar 1999 | A |
5879364 | Bromfield | Mar 1999 | A |
5882302 | Driscoll | Mar 1999 | A |
5894841 | Voges | Apr 1999 | A |
5895362 | Elstrom | Apr 1999 | A |
5904659 | Duarte | May 1999 | A |
5947921 | Johnson | Sep 1999 | A |
5957882 | Nita | Sep 1999 | A |
5960792 | Lloyd | Oct 1999 | A |
5964223 | Baran | Oct 1999 | A |
5989245 | Prescott | Nov 1999 | A |
6001069 | Tachibana | Dec 1999 | A |
6007499 | Martin | Dec 1999 | A |
6014970 | Ivri | Jan 2000 | A |
6024718 | Chen | Feb 2000 | A |
6026808 | Armer | Feb 2000 | A |
6027495 | Miller | Feb 2000 | A |
6036661 | Schwarze | Mar 2000 | A |
6041253 | Kost | Mar 2000 | A |
6061597 | Rieman | May 2000 | A |
6076519 | Johnson | Jun 2000 | A |
6083159 | Driscoll | Jul 2000 | A |
6095141 | Armer | Aug 2000 | A |
6098620 | Lloyd | Aug 2000 | A |
6102298 | Bush | Aug 2000 | A |
6104952 | Tu | Aug 2000 | A |
6106547 | Huei-Jung | Aug 2000 | A |
6113558 | Rosenschein | Sep 2000 | A |
6113570 | Siegel | Sep 2000 | A |
RE36939 | Tachibana | Oct 2000 | E |
6139320 | Hahn | Oct 2000 | A |
6158388 | Wenstrand | Dec 2000 | A |
6158431 | Poole | Dec 2000 | A |
6161536 | Redmon et al. | Dec 2000 | A |
6176839 | Deluis | Jan 2001 | B1 |
6186963 | Schwarze | Feb 2001 | B1 |
6190315 | Kost | Feb 2001 | B1 |
6190336 | Duarte | Feb 2001 | B1 |
6206842 | Tu | Mar 2001 | B1 |
6206843 | Iger | Mar 2001 | B1 |
6231528 | Kaufman | May 2001 | B1 |
6234990 | Rowe | May 2001 | B1 |
6251099 | Kollias | Jun 2001 | B1 |
6254294 | Muhar | Jul 2001 | B1 |
6273864 | Duarte | Aug 2001 | B1 |
6296630 | Altman et al. | Oct 2001 | B1 |
6311573 | Bhardwaj | Nov 2001 | B1 |
6314318 | Petty | Nov 2001 | B1 |
6321109 | Ben-Haim | Nov 2001 | B2 |
6322527 | Talish | Nov 2001 | B1 |
6325769 | Klopotek | Dec 2001 | B1 |
6392327 | Lewis | May 2002 | B1 |
6450417 | Gipson | Sep 2002 | B1 |
6458109 | Henley | Oct 2002 | B1 |
6478754 | Babaev | Nov 2002 | B1 |
6500133 | Martin et al. | Dec 2002 | B2 |
6533484 | Osei | Mar 2003 | B1 |
6533803 | Babaev | Mar 2003 | B2 |
6559365 | Wilfer | May 2003 | B2 |
6569099 | Babaev | May 2003 | B1 |
6583071 | Weidman | Jun 2003 | B1 |
6601581 | Babaev | Aug 2003 | B1 |
6623444 | Babaev | Sep 2003 | B2 |
6659365 | Gipson | Dec 2003 | B2 |
6663554 | Babaev | Dec 2003 | B2 |
6666431 | McCusker | Dec 2003 | B2 |
6723064 | Babaev | Apr 2004 | B2 |
6732744 | Olshavsky | May 2004 | B2 |
6761729 | Babaev | Jul 2004 | B2 |
6772967 | Bontems | Aug 2004 | B1 |
6830556 | Harmon | Dec 2004 | B2 |
6916296 | Soring | Jul 2005 | B2 |
6960173 | Babaev | Nov 2005 | B2 |
6964647 | Babaev | Nov 2005 | B1 |
7025735 | Soring | Apr 2006 | B2 |
7316664 | Kadziauskas | Jan 2008 | B2 |
7431704 | Babaev | Oct 2008 | B2 |
7572268 | Babaev | Aug 2009 | B2 |
7662177 | Babaev | Feb 2010 | B2 |
7713218 | Babaev | May 2010 | B2 |
7729779 | Babaev | Jun 2010 | B2 |
7753285 | Babaev | Jul 2010 | B2 |
7780095 | Babaev | Aug 2010 | B2 |
7785277 | Babaev | Aug 2010 | B2 |
7785278 | Babaev | Aug 2010 | B2 |
7830070 | Babaev | Nov 2010 | B2 |
7901388 | Babaev | Mar 2011 | B2 |
7914470 | Babaev | Mar 2011 | B2 |
8074896 | Ricciardi | Dec 2011 | B2 |
8491521 | Peterson | Jul 2013 | B2 |
8647720 | Staunton | Feb 2014 | B2 |
D733319 | Somers | Jun 2015 | S |
D733321 | Somers | Jun 2015 | S |
9070856 | Rose et al. | Jun 2015 | B1 |
9365341 | Bruna | Jun 2016 | B2 |
10603064 | Zhang | Mar 2020 | B2 |
20020000763 | Jones | Jan 2002 | A1 |
20020049463 | Friedman | Apr 2002 | A1 |
20020062093 | Soring | May 2002 | A1 |
20020080206 | Lin | Jun 2002 | A1 |
20020138036 | Babaev | Sep 2002 | A1 |
20020150539 | Unger | Oct 2002 | A1 |
20020156400 | Babaev | Oct 2002 | A1 |
20020177846 | Mulier et al. | Nov 2002 | A1 |
20030023193 | Soring | Jan 2003 | A1 |
20030125660 | Moutafis | Jul 2003 | A1 |
20030144627 | Woehr | Jul 2003 | A1 |
20030153961 | Babaev | Aug 2003 | A1 |
20030171701 | Babaev | Sep 2003 | A1 |
20030195644 | Borders | Oct 2003 | A1 |
20030216687 | Hwang | Nov 2003 | A1 |
20030236560 | Babaev | Dec 2003 | A1 |
20040015105 | Ito | Jan 2004 | A1 |
20040028552 | Bhardwaj | Feb 2004 | A1 |
20040030254 | Babaev | Feb 2004 | A1 |
20040034982 | Wieber | Feb 2004 | A1 |
20040055376 | Thompson | Mar 2004 | A1 |
20040068297 | Palti | Apr 2004 | A1 |
20040073175 | Jacobsen | Apr 2004 | A1 |
20040076175 | Patenaude | Apr 2004 | A1 |
20040091541 | Unger | May 2004 | A1 |
20040162509 | Tomohisa | Aug 2004 | A1 |
20040186384 | Babaev | Sep 2004 | A1 |
20040211260 | Girmonsky | Oct 2004 | A1 |
20050075587 | Vago | Apr 2005 | A1 |
20050075620 | Iger | Apr 2005 | A1 |
20050086023 | Ziegler | Apr 2005 | A1 |
20050203444 | Schonenberger | Sep 2005 | A1 |
20060025716 | Babaev | Feb 2006 | A1 |
20060058710 | Babaev | Mar 2006 | A1 |
20070016110 | Babaev et al. | Jan 2007 | A1 |
20070088245 | Babaev et al. | Apr 2007 | A1 |
20070090205 | Kunze | Apr 2007 | A1 |
20070299369 | Babaev | Dec 2007 | A1 |
20080051693 | Babaev | Feb 2008 | A1 |
20080110263 | Klessel | May 2008 | A1 |
20080132888 | Iida | Jun 2008 | A1 |
20080177221 | Millerd | Jul 2008 | A1 |
20080183109 | Babaev | Jul 2008 | A1 |
20080183200 | Babaev | Jul 2008 | A1 |
20080214965 | Peterson et al. | Sep 2008 | A1 |
20080234708 | Houser | Sep 2008 | A1 |
20080243047 | Babaev | Oct 2008 | A1 |
20080243048 | Babaev | Oct 2008 | A1 |
20080306501 | Babaev | Dec 2008 | A1 |
20090018491 | Babaev | Jan 2009 | A1 |
20090018492 | Babaev | Jan 2009 | A1 |
20090024076 | Babaev | Jan 2009 | A1 |
20090043248 | Peterson | Feb 2009 | A1 |
20090177122 | Peterson | Jul 2009 | A1 |
20090177123 | Peterson | Jul 2009 | A1 |
20090187136 | Babaev | Jul 2009 | A1 |
20090200394 | Babaev | Aug 2009 | A1 |
20090200396 | Babaev | Aug 2009 | A1 |
20090222037 | Babaev | Sep 2009 | A1 |
20090254005 | Babaev | Oct 2009 | A1 |
20100022919 | Peterson | Jan 2010 | A1 |
20100076349 | Babaev | Mar 2010 | A1 |
20100249882 | Houben | Sep 2010 | A1 |
20110285244 | Lewis et al. | Nov 2011 | A1 |
20120010506 | Ullrich | Jan 2012 | A1 |
20120223160 | Goodwin | Sep 2012 | A1 |
20130053697 | Holl | Feb 2013 | A1 |
20140276069 | Amble | Sep 2014 | A1 |
20150148712 | Loven | May 2015 | A1 |
20200179725 | Loven et al. | Jun 2020 | A1 |
Number | Date | Country |
---|---|---|
2421798 | Mar 2002 | CA |
2 359 426 | Apr 2002 | CA |
2436812 | Aug 2002 | CA |
1466445 | Jan 2004 | CN |
0 202 844 | Nov 1985 | EP |
0416106 | Mar 1991 | EP |
0 437 155 | Jul 1991 | EP |
0 657 226 | Nov 1994 | EP |
0 619 104 | Mar 2002 | EP |
1 199 047 | Apr 2002 | EP |
0 1564009 | Aug 2005 | EP |
3074089 | Dec 2020 | EP |
2099710 | Dec 1982 | GB |
2101500 | Jan 1983 | GB |
3-73168 | Mar 1991 | JP |
417844 | Apr 1992 | JP |
9135908 | May 1997 | JP |
2000237275 | Sep 2000 | JP |
878268 | Nov 1981 | SU |
910157 | Mar 1982 | SU |
1106485 | Oct 1982 | SU |
1176968 | Sep 1985 | SU |
1237261 | Jun 1986 | SU |
1827239 | May 1990 | SU |
1704847 | Jan 1992 | SU |
WO94-06380 | Mar 1994 | WO |
WO 96-35383 | Nov 1996 | WO |
WO02-24150 | Mar 2002 | WO |
WO 02-028350 | Apr 2002 | WO |
WO02-060525 | Aug 2002 | WO |
W0O2-095675 | Nov 2002 | WO |
WO 2007-002598 | Jan 2007 | WO |
WO 2009005980 | Jan 2009 | WO |
WO 2009102976 | Aug 2009 | WO |
WO 2016033041 | Mar 2016 | WO |
Entry |
---|
U.S. Appl. No. 90/007,613, filed Sep. 25, 2000, Babaev. |
Written Opinion for International Application No. PCT/US06/24833, dated Feb. 22, 2007, 5 pages. |
Zharov et al, “Comparison Possibilities of Ultrasound and Its Combination with Laser in Surgery and Therapy”, pp. 331-339, In Biomedical Optoacoustics. |
Asakawa, M. et al., “WBN-Kob-Ht Rats Spontaneously Develop Dermatitis Under Conventional Conditions: Another Possible Model for Atopic Dermatitis,” Exp. Anim.,54(5): pp. 461-465 (2005). |
Bisno, Alan.L., et al. , “Murine Model of Recurrent Group G Streptococcal Cellulitis: No Evidence of Proective Immunity,” Infection and Immunity, vol. 65 No. 12, pp. 4926-4930 © 1997. |
Brooks, R.R., , “Canine Carrageenin-Induced Actue Paw Inflammation Model and its Response to Nonsteroidal Antiinflammatory Drugs,” J. Parrnacol Methods, 25, pp. 275-283 © 1991. |
Chen, L. et al., The Disease Progression in the Keratin 14 IL-4-transgenic Mouse Model of Atopic Dermatitis Parallels the Up-regulation ofB Cell Activation Molecules, Proliferation and Surface and Serum lg;E, Clin, Exp. Immunolo, 142: 21-30 © 2005. |
Chinese Office Action, dated May 22, 2009 for Chinese Application No. 2006800927860, 9 pages. |
Department of Health & Human Services Letter dated Jun. 25, 2004, 3 pages. |
Department of Health & Human Services Letter Dated May 17, 2005, 3 pages. |
Zharov et al., Design and Application of Low-Frequency Ultrasound and Its Combination With Laser Radiation in Surgery and Therapy, Critical Reviews in Biomedical Bngineering; No. 4, 2000, pp. 502-519. |
Dong, Cheng, et al., “MAP Kinases in the Immune Response,” Annu. Rev. Immunol., 20: 55-72 © 2002. |
Ennis, William J. et al. “Ultrasound Therapy for Recalcitrant Diabetic Foot Ulcers: Results of a Randomized, Double-Blind, Controlled, Multicenter Study”, Ostomy/Wound Management 2005; 51(8): pp. 24-39. |
European Examination Report for European Application No. 01 973 554.8. dated Feb. 9, 2010, 3 pages. |
European Examination Report for European Application No. 08 866 666.4, dated Mar. 22, 2011, 5 pages. |
European Office Action from European Application No. EP01973544.8 dated Dec. 16, 2011, 4 pages. |
European Search Report corresponding to European Application No. 01973544.8-2107—U.S. Pat. No. 0,130,096, Applicant Advanced Medical Applications Inc., dated Sep. 13, 2004, 5 pages. |
European Search Report, European Application No. 01973544.8-2107—U.S. Pat. No. 0,130,096, dated Sep. 13, 2004, 5 pages. |
European Search Report for European App. 02709235, dated Apr. 4, 2006. |
European Search Report for European App. 02709235.2-2305., dated Apr. 18, 2006. |
European Supplementary Search Report corresponding to European Application No. 01973544, dated Sep. 1, 2004. |
European Supplementary Search Report corresponding to European Application No. 02709235, dated Apr. 4, 2006. |
Examination Report, dated Dec. 5, 2007, for Indian App. 1078-MUMNP-2005. |
Examination Report, dated Jul. 1, 2008, for European App. 02709235.2-2305, 4 pages. |
Examination Report, dated Nov. 21, 2007, for European App. 02709235.2-2305, 4 pages. |
Hammer, Robert E. et al. , “Spontaneous Inflammatory Disease in Transgenic Rats Expressing HLA-B27 and Human β2m: An Animal Model ofHLA-B27-Associated Human Disorders,” Cell, vol. 63, pp. 1099-1112, © 1990. |
Haqqi, Tariq M., et al., “Restricted Heterogeneity in T-cell Antigen Receptor Vβ Gene Usage in the Lymph Nodes and Arthritic Joints of Mice,” Proc. Natl. Acad. Sci. USA, vol. 89: 1253-1255, Feb. 1992. |
Hurvitz, A.I., “Animal Model of Human Disease, Pemphigus Vulgaris, Animal Model: Canine Pemphigus Vulgaris,” American Journal of Pathology, 98(3): 861-864 (1980). |
International Search Report for EP 04749758.1-2319, dated Mar. 30, 2011, 5 pages. |
International Search Report for PCT/US2004/010448, dated Nov. 10, 2004, 4 pages. |
International Search Report for PCT/US01/31226, dated Sep. 11, 2002, 1 page. |
International Search Report for PCT/US01/30096, dated Sep. 25, 2002, 1 page. |
International Search Report for PCTUS02/02724, dated Dec. 11, 2002, 3 pages. |
International Search Report for PCTUS06/24833, dated Feb. 22, 2007, 1 page. |
International Search Report for PCT/US2007/026251, dated May 7, 2008, 2 pages. |
International Search Report for PCT/US2008/000151, dated Apr. 21, 2008, 4 pages. |
International Search Report for PCT/US95/14926, dated Feb. 27, 1996, 1 page. |
Iraniha, Seed, et al. “Determination of Burn Depth With Noncontact Ultrasonography,” J. Burn Care Rehabil., 21:333-338, Jul./Aug. 2000. |
Janeway, Charles A. et al., “Innate Immune Recognition”, Annual Review of Immunology 20: 197-216, © 2002. |
Japanese Notification of Reasons for Rejection from Japanese Application No. 2008-518449 dated Jul. 29, 2011. |
Japanese Office Action, dated Dec. 18, 2009 for Japanese Application No. 2002-528187. |
Japanese Office Action, dated Jul. 29, 2010 for Japanese Application No. 2002-528187. |
Bina, Joe et al. “Animal Models of Rheumatoid Arthritis,” Molecular Medicine Today, vol. 5, Aug. 1999, pp. 367-369. |
Keffer, Jeanne , “Transgenic Mice Expressing Human Tumour Necrosis Factor: A Predictive Genetic Model of Arthritis,” The EMBO Journal, vol. 10, No. 13, pp. 4025-4031 (1991). |
Liu, Z. et al., “Immunopathological Mechanisms of Acantholysis in Pemphigus Vulgaris: An Explanation by Ultrastructural Observations,” The Journal of Investigative Dermatology, © 2004. |
Nishimuta, K. et al., “Effects of Metronidazole and Tinidazole Ointments on Models for Inflammatory Dermatitis in Mice,” Arch. Dermatol. Res., 294: 544-551 (2003). |
Office Action and Machine Translation Summary of Office Action, dated Apr. 25, 2006, for Mexican App. PA-a-2003-002535, 3 pages. |
Office Action and Machine Translation Summary of Office Action, dated Jul. 7, 2008, for Mexican App. PA-a-2003-002535, 3 pages. |
Office Action dated Apr. 24, 2007, for Japanese App. No. 2002-560715 now JP-4,164,582, 3 pages. |
Office Action, dated Apr. 20, 2007, for Chinese App. 01816263.0, 8 pages. |
Office Action, dated Aug. 14, 2007, for Canadian App. 2,421,798, 3 pages. |
Office Action, dated Aug. 5, 2009, for Canadian App. 2,421,798, 3 pages. |
Office Action, dated Jan. 14, 2010, for Canadian App. 2,436,812, 3 pages. |
Office Action, dated Jan. 18, 2008, for Chinese App. 01816263.0, 11 pages. |
Office Action, dated May 18, 2006, for Canadian App. 2,421,798, 4 pages. |
Office Action, dated May 3, 2006, for Canadian App. 2,436,812, 2 pages. |
Office Action, dated Nov. 2, 2009, for Canadian App. 2,521,117, 3 pages. |
Office Action, dated Nov. 5, 2009, for Japanese App. 2006-509708, 3 pages. |
Office Action, dated Sep. 12, 2006, for Canadian App. 2,463,600, 3 pages. |
Office Action, dated Sep. 26, 2007, for Canadian App. 2,521,117, 3 pages. |
Pelletier, Jean-Pierre et al., “In vivo Suppression of Early Experimental Osteoarthritis by Interleukin-1 Receptor Antagonist Using Gene Therapy,” Arthritis & Rheumatism, vol. 40, No. 6, pp. 1012-1019, Jun. 1997. |
Schon, Michael P. “Animal Models of Psoriasis—What Can We Learn from Them?”, The Journal of Investigative Dermatology, 112(4): 405-410 © 1999. |
Trentham, David E., Autoimmunity to Type II Collagen: An Experimental Model of Arthritis, The Journal of Experimental Medicine, vol. 146, 1977. |
Wooley, Paul H. , “Type II Collagen-Induced Arthritis in Mice, I. Major Histocompatibility Complex (I Region) Linkage and Antibody Correlates,” J. Exp. Med., vol. 154, pp. 688-700, Sep. 1981. |
XP-002294548, Abstract corresponding to SU 914099. |
Yamamoto, Toshiyuki, “Characteristics of Animal Models for Scleroderma,” Current Rheumatology Reviews, vol. 1, No. 1, pp. 101-109, (2005). |
Application and File History for U.S. Appl. No. 09/704,099, filed Nov. 1, 2000, now U.S. Pat. No. 6,601,581, issued Aug. 5, 2003, Inventor: Bilaz Babaev. |
Application and File History for U.S. Appl. No. 09/774,145, filed Jan. 30, 2001, now U.S. Pat. No. 6,960,173, issued Nov. 1, 2005, Inventor: Eilaz Babaev. |
Application and File History for U.S. Appl. No. 09/840,416, filed Apr. 23, 2001, now U.S. Pat. No. 6,478,754, issued Nov. 12, 2002, Inventor: Eilaz Babaev. |
Application and File History for U.S. Appl. No. 10/214,339, filed Aug. 7, 2002, now U.S. Pat. No. 6,663,554, issued Dec. 16, 2003, Inventor: Eilaz Babaev. |
Application and File History for U.S. Appl. No. 09/669,312, filed Aug. 7, 2002, now U.S. Pat. No. 6,569,099, issued May 27, 2003, Inventor: Eilaz Babaev. |
Application and File History for U.S. Appl. No. 10/409,272, filed Apr. 7, 2003, now U.S. Pat. No. 8,235,919, issued Aug. 7, 2012, Inventor: Eilaz Babaev. |
Application and File History for U.S. Appl. No. 10/815,384, filed Apr. 1, 2004, now U.S. Pat. No. 7,914,470, issued Mar. 29, 2011, Inventor: Eilaz Babaev. |
International Search Report, International Application No. PCT/US2014/066159, dated Mar. 24, 2015, 14 pages. |
Examination Report for EP 04749758.1-2319, dated Apr. 30, 2010, 3 pages. |
Clark, Richard A.F., The Molecular and Cellular Biology of Wound Repair, Second Edition, Wound Repair: Overview and General Considerations, Chapter 1, pp. 3-49. |
International Preliminary Report on Patentability, International Application No. PCT/US2014/066159, dated Jun. 9, 2016, 10 pages. |
International Search Report and Written Opinion, International Application No. PCT/US17/44323, dated Oct. 25, 2017, 16 pages. |
Amemark, Quick Reference Guide, Jun. 2015, 1 page. |
European Search Report, Application No. 14865354.6, dated Jun. 28, 2017, 8 pages. |
International Preliminary Report on Patentability, Application No. PCT/US2017/044323, dated Feb. 7, 2019, 10 pages. |
Australian Examination Report, Application No. 2014355072, dated Aug. 29, 2018, 5 pages. |
European Examination Report, Application No. 14865354.6, dated Jun. 18, 2019, 7 pages. |
Tektronix, User Manual, AFG310 and AFG320 Arbitrary Function generator, 071-0175-50, www.tektronix.com, 276 pages. |
Gage Applied Technologies, CompuGen ISA Hardware Manual and Driver Installation Guide, Reorder #: MKT-HWM-ISA01 0506, www.gage-applied.com, Jun. 2005, 38 pages. |
Harmonic Generator 300 System Service Manual, Ethicon Endo-Surgery, LLC, Johnson & Johnson Company, P40401POX, 80 pages (undated, copyright notice of 2007). |
Australian Examination Report, Application No. 2019219713, dated Mar. 19, 2020, 5 pages. |
Quora, What are Resonant Frequencies?, available at https://www.quora.com/What-are-resonant-frequencies#, retrieved on Jul. 27, 2020. |
European Examination Report, European Application No. 14 865 354.6, dated Mar. 16, 2021, 8 pages. |
Canadian Office Action, Canadian Application No. 2,931,612, dated Dec. 30, 2020, 4 pages. |
Number | Date | Country | |
---|---|---|---|
20150148712 A1 | May 2015 | US |
Number | Date | Country | |
---|---|---|---|
61909086 | Nov 2013 | US |